Small Molecule Destabilizer of β-Catenin and Ras Proteins Antagonizes Growth of K-Ras Mutation-Driven Colorectal Cancers Resistant to EGFR Inhibitors

ConclusionsCPD0857 may be a potential drug for treating aggressive CRC carrying mutations that aberrantly activate Wnt/ β-catenin and Ras-ERK pathways.

http://link.springer.com/10.1007/s11523-020-00755-5

Source: Targeted Oncology - October 6, 2020 Category: Cancer & Oncology Source Type: research